Welcome to our dedicated page for Revium Recovery news (Ticker: RVRC), a resource for investors and traders seeking the latest updates and insights on Revium Recovery stock.
Revium Rx reports developments in lipid-based and nanoparticle therapeutics for infectious and oncologic diseases. The company, formerly Revium Recovery Inc., shifted its operating focus through the completed acquisition of LipoVation Ltd., an Israeli development-stage company specializing in lipid-based nano and micro particle medicines.
Recurring RVRC news centers on Nano-Mupirocin, a systemic formulation of the antibiotic mupirocin designed for severe bacterial infections, including multidrug-resistant pathogens. Company updates also cover regulatory and manufacturing preparations for clinical development, product-development partnerships, material agreements, shareholder voting matters, capital-structure disclosures, and leadership changes.
Revium Rx (OTC: RVRC) announced progress toward a planned Phase 1 clinical trial of Nano-Mupirocin, a systemic nano-liposomal formulation of mupirocin designed to treat multidrug-resistant infections.
Key milestones: the company submitted a clinical trial application to the Israeli Ministry of Health on Oct 21, 2025, and is scaling up GMP clinical batch production with WuXi AppTec, targeting final release by end of 2025 and first-in-human studies in early 2026. The release highlights target indications (MRSA, VRE, CR-gonorrhea) and cites a global AMR therapeutics market projected to exceed $12.5B by 2030.
Revium Rx (RVRC) has completed the acquisition of LipoVation , an Israeli development-stage company specializing in lipid-based nano/micro particle medicines. The acquisition positions Revium at the forefront of advanced drug delivery technologies and marks a strategic shift toward nanoparticle-based therapeutics.
The company's pipeline includes three key programs: a novel systemic antibiotic formulation, an adjuvant for cancer immunotherapies, and an innovative immunization approach. These therapeutics are built on proprietary technologies including clinically validated nanoparticles, advanced drug-loading systems, and specialized lipid-based carriers.
Following the acquisition, David Akunis has been appointed CEO, while former CEO Inna Martin has transitioned to COO and President. LipoVation's core technology was developed by Prof. Yehezkel Barenholz, inventor of Doxil, the first FDA-approved liposomal chemotherapy drug.
Revium Recovery, Inc. (OTC Pink: RVRC) has signed a non-binding letter of intent to acquire LipoVac, Ltd., a private company specializing in advanced liposomal technologies. The acquisition involves an exchange of outstanding LipoVac shares for RVRC stock, resulting in LipoVac shareholders owning 20% to 40% of RVRC post-transaction. A condition for closing is a $7 million private placement by RVRC. The merger is expected to enhance shareholder value through R&D investments and strategic acquisitions, positioning the combined entity for significant growth in the biotech sector.